- Home
- CHNR vs RDHL Comparison
CHNR vs RDHL Comparison
Compare CHNR & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHNR | RDHL |
|---|---|---|
| Founded | N/A | 2009 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7M | 3.9M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | CHNR | RDHL |
|---|---|---|
| Price | $3.94 | $1.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 19.1K | ★ 69.6K |
| Earning Date | 12-12-2025 | 09-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,550,000.00 |
| Revenue This Year | N/A | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 157.62 |
| 52 Week Low | $3.16 | $1.01 |
| 52 Week High | $8.20 | $7.44 |
Technical Indicators
Market Signals| Indicator | CHNR | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 45.79 | 48.81 |
| Support Level | $3.75 | $1.18 |
| Resistance Level | $4.31 | $1.26 |
| Average True Range (ATR) | 0.27 | 0.06 |
| MACD | 0.10 | 0.02 |
| Stochastic Oscillator | 43.35 | 73.87 |
Price Performance
Historical ComparisonAbout CHNR China Natural Resources Inc.
China Natural Resources Inc is engaged in exploration for lead, silver, and other metals in the Inner Mongolia Autonomous Region of the PRC and exploration of attractive opportunities in other sectors. The company has a single operating segment: exploration and mining.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.